Shire Secures FDA Approval for HAE Drug Lanadelumab

Shire plc snagged approval from the U.S. Food and Drug Administration (FDA) for Takhzyro (lanadelumab-flyo), a prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.